Previous studies have shown that targeting EGFR signaling results in acute upregulation of alternative receptor tyrosine kinases (RTK) in GBM, such as ERBB2, MET, and PDGFRβ [2, 19, 24]. This evidence concerns the gene ERBB2 and glioblastoma.